MarcieRichesMDMS

Oncology • Chapel Hill, NC

Hematologic Oncology

Professor, University of North Carolina Director, BMT Program

Join to view full profile

Dr. Riches is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Riches' full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 919-966-3048

Fax+1 919-966-6735

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Kentucky College of MedicineResidency, Internal Medicine, 1996 - 1999
University of Kentucky College of MedicineClass of 1997

Certifications & Licensure

NC State Medical License 2015 - 2025
FL State Medical License 2009 - 2017
MN State Medical License 2004 - 2010
IL State Medical License 2000 - 2005
KY State Medical License 1998 - 2001
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Start of enrollment: 2003 Sep 01
Terminated
Phase 1
Zevalin-beam for Aggressive Lymphoma Start of enrollment: 2007 Jun 01
Completed
Phase 3
Phase II Trial of Pentostatin and Targeted Busulfan Start of enrollment: 2007 Jul 01
Completed
Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
Completed
Phase 1, Phase 2
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2014 Oct 29
Completed
Phase 1
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Start of enrollment: 2013 Aug 01
Completed
Phase 3
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Start of enrollment: 2014 Mar 25
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
Joshua A Hill, Michael J Martens, Jo-Anne H Young, Kavita Bhavsar, Jianqun Kou
Clinical Infectious Diseases. 2024-08-16
3 citations
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30lymphoma: a phase 1 study.
Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore
The Lancet. Haematology. 2024-05-01
1 citations
Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee.
Zainab Shahid, Aaron M Etra, John E Levine, Marcie L Riches, Aliyah Baluch
Transplantation and Cellular Therapy. 2024-05-01

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica

Press Mentions

COVID-19 Prevention Is Essential for Bone Marrow Transplant PatientsFebruary 9th, 2021